JP3989951B2 - 組み合わせ髄膜炎ワクチン - Google Patents

組み合わせ髄膜炎ワクチン Download PDF

Info

Publication number
JP3989951B2
JP3989951B2 JP51517596A JP51517596A JP3989951B2 JP 3989951 B2 JP3989951 B2 JP 3989951B2 JP 51517596 A JP51517596 A JP 51517596A JP 51517596 A JP51517596 A JP 51517596A JP 3989951 B2 JP3989951 B2 JP 3989951B2
Authority
JP
Japan
Prior art keywords
vaccine
antibody
prp
infants
hib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51517596A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10509701A (ja
Inventor
コスタンテ セッカリーニ，
パオロ コスタンティーノ，
サンドロ ダアスセンジ，
フランシスコ ノレッリ，
アルド ギアノッジ，
Original Assignee
カイロン ソチエタ ア レスポンサビリタ リミタータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10763774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3989951(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by カイロン ソチエタ ア レスポンサビリタ リミタータ filed Critical カイロン ソチエタ ア レスポンサビリタ リミタータ
Publication of JPH10509701A publication Critical patent/JPH10509701A/ja
Application granted granted Critical
Publication of JP3989951B2 publication Critical patent/JP3989951B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP51517596A 1994-11-02 1995-11-02 組み合わせ髄膜炎ワクチン Expired - Fee Related JP3989951B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9422096A GB9422096D0 (en) 1994-11-02 1994-11-02 Combined meningitis vaccine
GB9422096.9 1994-11-02
PCT/IB1995/001006 WO1996014086A1 (en) 1994-11-02 1995-11-02 Combined meningitis vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007083117A Division JP4871770B2 (ja) 1994-11-02 2007-03-27 組み合わせ髄膜炎ワクチン

Publications (2)

Publication Number Publication Date
JPH10509701A JPH10509701A (ja) 1998-09-22
JP3989951B2 true JP3989951B2 (ja) 2007-10-10

Family

ID=10763774

Family Applications (3)

Application Number Title Priority Date Filing Date
JP51517596A Expired - Fee Related JP3989951B2 (ja) 1994-11-02 1995-11-02 組み合わせ髄膜炎ワクチン
JP2007083117A Expired - Fee Related JP4871770B2 (ja) 1994-11-02 2007-03-27 組み合わせ髄膜炎ワクチン
JP2010236921A Withdrawn JP2011016850A (ja) 1994-11-02 2010-10-21 組み合わせ髄膜炎ワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007083117A Expired - Fee Related JP4871770B2 (ja) 1994-11-02 2007-03-27 組み合わせ髄膜炎ワクチン
JP2010236921A Withdrawn JP2011016850A (ja) 1994-11-02 2010-10-21 組み合わせ髄膜炎ワクチン

Country Status (12)

Country Link
US (1) US6251401B1 (enExample)
EP (3) EP0789587B2 (enExample)
JP (3) JP3989951B2 (enExample)
AT (1) ATE246936T1 (enExample)
CA (2) CA2689871A1 (enExample)
CY (1) CY2423B1 (enExample)
DE (1) DE69531501T3 (enExample)
DK (1) DK0789587T4 (enExample)
ES (1) ES2204967T5 (enExample)
GB (1) GB9422096D0 (enExample)
PT (1) PT789587E (enExample)
WO (1) WO1996014086A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007169302A (ja) * 1994-11-02 2007-07-05 Chiron Srl 組み合わせ髄膜炎ワクチン

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE208629T1 (de) 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
EP0922059B1 (en) 1996-08-27 2003-10-22 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
EP0980257A1 (en) * 1997-05-01 2000-02-23 Chiron Corporation Use of virus-like particles as adjuvants
US20040087020A1 (en) 1997-05-28 2004-05-06 Chiron S.P.A. Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin
ES2293681T3 (es) * 1997-05-28 2008-03-16 Novartis Vaccines And Diagnostics S.R.L. Medio de cultivo con extracto de soja como fuente de aminoacidos pero sin complejos proteinicos de origen animal.
US20070259007A1 (en) * 1999-10-19 2007-11-08 Kruzel Marian L Lactoferrin: an adjuvant for vaccines
DK1233784T3 (da) * 1999-12-02 2008-09-01 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til stabilisering af biologiske molekyler efter lyofilisering
EP2279748A1 (en) * 2000-06-29 2011-02-02 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
EP1379272B1 (en) 2001-04-17 2010-01-20 Novartis Vaccines and Diagnostics, Inc. Monoclonal antibodies directed against molecular mimetics of meningococcal b epitopes
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US20030124139A1 (en) * 2002-11-20 2003-07-03 Irina Esikova Compositions and methods for stabilizing biological molecules upon lyophilization
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
SI1670506T1 (sl) 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
JP2008543907A (ja) * 2005-06-27 2008-12-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
JP5637848B2 (ja) * 2007-06-04 2014-12-10 ノバルティス アーゲー 髄膜炎ワクチンの製剤化
DK2200642T3 (da) * 2007-10-19 2012-07-16 Novartis Ag Meningococvaccinepræparater
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
DK3831406T3 (da) 2010-08-23 2024-06-17 Wyeth Llc Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3270959A1 (en) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis compositions and methods thereof
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
KR102871663B1 (ko) 2019-09-27 2025-10-16 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5628496A (en) 1995-06-07 1997-05-13 Avm, Inc. Pneumatic spring
EP0922059B1 (en) * 1996-08-27 2003-10-22 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007169302A (ja) * 1994-11-02 2007-07-05 Chiron Srl 組み合わせ髄膜炎ワクチン
JP2011016850A (ja) * 1994-11-02 2011-01-27 Chiron Srl 組み合わせ髄膜炎ワクチン

Also Published As

Publication number Publication date
CA2204277C (en) 2010-02-02
JP4871770B2 (ja) 2012-02-08
ES2204967T3 (es) 2004-05-01
EP1312377A3 (en) 2004-02-04
EP2204185A1 (en) 2010-07-07
JP2011016850A (ja) 2011-01-27
ES2204967T5 (es) 2008-07-01
CA2689871A1 (en) 1996-05-17
DE69531501D1 (de) 2003-09-18
DK0789587T3 (da) 2003-12-01
GB9422096D0 (en) 1994-12-21
JP2007169302A (ja) 2007-07-05
DK0789587T4 (da) 2008-08-04
ATE246936T1 (de) 2003-08-15
EP2204185A8 (en) 2010-10-27
EP0789587B1 (en) 2003-08-13
US6251401B1 (en) 2001-06-26
EP0789587B2 (en) 2008-04-02
CA2204277A1 (en) 1996-05-17
EP0789587A1 (en) 1997-08-20
DE69531501T2 (de) 2004-06-24
WO1996014086A1 (en) 1996-05-17
DE69531501T3 (de) 2008-11-13
CY2423B1 (en) 2004-11-12
PT789587E (pt) 2003-12-31
EP1312377A2 (en) 2003-05-21
JPH10509701A (ja) 1998-09-22

Similar Documents

Publication Publication Date Title
JP4871770B2 (ja) 組み合わせ髄膜炎ワクチン
Anderson et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults
FERRECCIO et al. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age
Frasch Vaccines for prevention of meningococcal disease
Granoff et al. Prospects for prevention of Haemophilus influenzae type b disease by immunization
Austrian Pneumococcal polysaccharide vaccines
Lepow et al. Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age
Anderson et al. Phenotypic and genetic variation in the susceptibility of Haemophilus influenzae type b to antibodies to somatic antigens
Peltola et al. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides
Paoletti et al. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines
Heininger et al. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany
Pichichero et al. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussisvs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18-to 24-month old children
Pichichero et al. Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine
Guttormsen et al. Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease
RU2121365C1 (ru) Комбинированная вакцина, способ одновременной комбинированной вакцинации и способ повышения иммуногенности
Granoff et al. Comparative immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines
Joshi et al. Meningococcal polysaccharide vaccines: A review
Robbins et al. Haemophilus influenzae type b
Vodopija et al. Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide
Panpitpat et al. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine
GIGLIOTTI et al. Immunodeficiency associated with recurrent infections and an isolated in vivo inability to respond to bacterial polysaccharides
Aftandelians et al. Bactericidal antibody in serum during infection with Bordetella pertussis
HK1056503A (en) Combined meningitis vaccine
HK1143954A (en) Combined meningitis vaccine
Nolan et al. Antibody response to infection in multiple myeloma: implications for vaccination

Legal Events

Date Code Title Description
A72 Notification of change in name of applicant

Free format text: JAPANESE INTERMEDIATE CODE: A721

Effective date: 20060120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060629

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070327

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070719

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100727

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110727

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110727

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120727

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120727

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130727

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees